Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.

This study found that GLP1-RAs, while not triggering significant safety signals, were reported more often for suicide, hair loss, and aspiration events compared to some other diabetes medications.

This study found that children with alopecia areata had higher levels of oxidative stress markers but showed no significant differences in depression and suicide tendencies compared to healthy peers.

This study found that reports of suicidal ideations linked to oral finasteride were significantly higher in 2013–2018 and 2019–2023 compared to 2006–2011, potentially due to increased awareness of post-finasteride syndrome from 2012 onward. No such signals were seen with oral dutasteride.

Finasteride and dutasteride may increase the risk of suicide and sexual dysfunction.

Dr. Mayer Brezis argues that a study by Wang et al. incorrectly concluded that finasteride does not cause depression or suicide, due to methodological flaws, and suggests halting its marketing under the precautionary principle.

In this letter, Dr. Mayer Brezis critiques a study on finasteride's mental health impact, arguing that its dismissal of links between the drug and depression or suicide is flawed; he suggests market withdrawal due to established neuropsychiatric risks.

This study found that finasteride is associated with significant depressive effects, including an increased risk of suicidality, which can persist beyond 20 months after stopping the medication, even without prior sexual dysfunction or psychiatric history.

This study found that men using 5-alpha-reductase inhibitors showed an increased risk for dementia shortly after starting treatment, which diminished over time, and a consistent association with depression, but no link to suicide.

This article reviews the use of isotretinoin for acne treatment and its controversial association with depression and suicide, noting limited evidence for a direct link.

In this study, the researchers found no link between finasteride use and increased suicide attempt risk among Danish males, noting unadjusted and adjusted odds ratios close to one.

This study found that finasteride use is not significantly associated with an increased risk of depression or suicide, based on Mendelian randomization analysis and COX regression analysis in a large UK Biobank cohort.

This study suggests that men under 40 who develop persistent sexual side effects and insomnia after using finasteride for alopecia may be at increased risk of suicide.

In this study, men under 40 using finasteride for alopecia who experienced persistent sexual side effects and insomnia were reportedly at risk for suicide.

In this systematic review and meta-analysis, the authors found no statistically significant association between the use of 5α-reductase inhibitors and the risk of depression or suicide among over two million studied patients.

Finasteride may lower depression risk in younger men with hair loss but increase it in older men with prostate issues.

Finasteride use for hair loss is linked to an increased risk of suicidal thoughts and a higher risk of suicide.

The conclusion is that finasteride is linked to an increased risk of suicidal thoughts and a higher risk of completed suicide when used for hair loss.

In this study, the use of finasteride in young patients may be linked to a higher risk of anxiety, depression, and suicide-related adverse events.

This cohort study found no overall increased risk of suicidal behaviors with finasteride versus dutasteride in men aged 50 and older, but suggested potential risk for those with a history of mood disorders.

This nested case-control study observed that patients with benign prostatic hyperplasia or androgenic alopecia who had a cumulative 5-ARI dose exceeding 5840 defined daily doses had a significantly reduced mortality risk, while lower doses were linked to higher mortality and suicide rates.

This study found that seniors using finasteride or dutasteride for benign prostatic hyperplasia may have an increased risk of depression and self-harm, especially during the first 18 months of treatment.

This study suggests that using finasteride for alopecia or BPH may be less associated with suicidality and psychological adverse events when combined with PDE5 inhibitors or testosterone, possibly offering protective benefits.

Results are not reported in this commentary, but it discusses the influence of different control group choices—an active-comparator versus non-drug users—on measuring depression risk in studies of 5-alpha reductase inhibitors.

This article provides no new research results, focusing instead on International Consortium for Mood and Psychotic Disorder Research's topics and types of collaborations.

This review discusses the mechanisms by which isotretinoin and hormonal therapy treat acne through their effects on sebaceous glands, reporting no new clinical results.

Finasteride, a hair loss drug, is linked to increased suicidal thoughts, particularly when used for hair loss.

This pharmacovigilance study analyzed FAERS data and found that finasteride is more frequently associated with neuropsychiatric reactions like depression and suicide risk, especially in younger men using it for alopecia, compared to dutasteride.

This article compiles various topics in psychodermatology, such as suicide risk, treatment options, and the psychological impact of conditions like alopecia, but reports no new clinical findings.